Affymax (AFFY)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Jun 7, 2024 11:49 AM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Affymax Inc. [AFFY]
Reports for Purchase
Showing records 41 - 55 ( 55 total )
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
3Q11 Review: Gets JNJ off its Back; All Eyes on December Panel
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
2Q11 Results Review: Hematide at the FDA; Panel and EU Filing on Track for 1H12
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for AFFY
Provider: VALUENGINE, INC
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Lots of News Flow Ahead; Adjusting Estimates to Reflect Timing of Takeda Payments.
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
1Q11 Results Review: Continued Progress; Hematide NDA Filing on Track for 2Q11
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Hematide Could Rise Again - Upgrading to Buy and Increasing Price Target to $10
Provider: AURIGA USA
Analyst: MEHRA R
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Hematide Could Rise Again - Upgrading to Buy and Increasing Price Target to $10
Provider: AURIGA USA
Analyst: MEHRA R
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
3Q10 Results Review: All Eyes on Hematide - FDA Update Likely Near Term
Provider: AURIGA USA
Analyst: MEHRA R
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
2Q10 Results Review: Essentially In-Line; FDA Discussions Planned for Late 2010
Provider: AURIGA USA
Analyst: MEHRA R
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Hematide Approval in Doubt; Downgrading Rating to Hold
Provider: AURIGA USA
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
1Q10 Results Review: No Surprises; Hematide Phase III Loomin.
Provider: AURIGA USA
Company: Affymax Inc.
Industry: Medical - Biomedical and Genetics
Next Generation ESA : Initiate with a Buy Rating
Provider: AURIGA USA